semaglutide stomach paralysis attorney in louisiana vomiting lawyer louisiana semaglutide nausea lawyer semaglutide ileus louisiana GLP-1 Medications The GLP-1 RA Legal Timeline:

Outcomes The extension addressed two exploratory objectives: (1) to examine the change in body weight and cardiometabolic risk factors in participants who completed treatment in the main phase and were followed during the offtreatment period

Adequate hydration can reduce nausea, improve digestion, and support energy levels

licensed physicians BBB Rating: Delivery & Access Format: Subcutaneous Nationwide telehealth: Yes (all 50 states) Speed: Fast Spanish-speaking providers: Not available Start your GLP-1 weight loss journey with Peak Wellness today Medical Disclaimer: This review is for informational purposes only and does not constitute medical advice

2024 Oct 15;44(11):NP809-NP818

According to the MHRA/EMC SmPC for Wegovy, the most frequently reported gastrointestinal side effects include: Nausea the most common adverse effect, affecting approximately 44% of patients in clinical trials, typically most pronounced during dose escalation Diarrhoea reported in around 30% of patients, ranging from mild to moderate severity Constipation affecting approximately 24% of patients, related to slowed gut transit Vomiting occurring in roughly 24% of patients, often associated with nausea Abdominal pain or discomfort reported by approximately 20% of patients Dyspepsia (indigestion) affecting around 9% of patients Bloating and flatulence commonly reported but less precisely quantified in trials These side effects are dose-dependent , meaning they tend to be more pronounced at higher doses and during the escalation phase